Verification of renal tissue regeneration using human perinephric fat-derived collagen sheet in a partially nephrectomized animal model.
Kim BS., Lee EH., Yoon BH., Jeon M., Kang JK., Chung JW.
Animal Study on Chronic Kidney Disease, Scar, Chronic Inflammation, published in J Biomater Appl (2026) — summary generated from the PubMed abstract.
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Biomater Appl (2026)
- Country
- England
- Reported sample size
- —
- PMID
- 41247038
- DOI
- 10.1177/08853282251399548
Abstract (original English)
Chronic kidney disease (CKD), a global health issue, affects approximately 10% of the population. However, limited treatment options, such as dialysis or transplantation, have significant drawbacks. Therefore, this study aims to investigate the potential of a collagen sheet derived from human perirenal adipose tissue for kidney regeneration. Collagen sheets were derived from discarded perirenal adipose tissues and implanted into partially nephrectomized mice. The right kidneys were completely removed, and 2 mm of the upper and lower poles of the left kidneys were resected. A collagen sheet measuring 1 × 1 × 3 mm 3 was implanted in the mid-pole of the left kidney following partial resection of renal parenchyme. Renal function, inflammation, and tissue regeneration were evaluated using serum analysis, PCR, histological staining, and immunohistochemistry to assess structural and functional improvements. The collagen sheet reduced pro-inflammatory markers, minimized fibrosis, and restored renal function indicators such as BUN and cystatin C, though creatinine levels remained unchanged. Regenerative markers, including PAX2 and Wt1, were significantly elevated, indicating enhanced tissue repair and structural recovery. The perirenal adipose tissue-derived collagen sheet demonstrated anti-inflammatory effects and promoted renal tissue regeneration. These findings suggest its potential
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence comes from animal or laboratory studies and has not been confirmed in humans.
How we grade evidenceRelated research
- Level ASystematic Review
Clinical Safety and Efficacy of Allogeneic Adipose Stem Cells: A Systematic Review of the Clinical Trials.
Systematic Review with a reported sample of 953 on Osteoarthritis, Chronic Kidney Disease, Scar, Autoimmune Research, published in Int J Mol Sci (2025) — summary generated from the PubMed abstract.
- 2025
- n = 953
Int J Mol Sci - Level AMeta-analysis
A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease.
Meta-analysis on Chronic Kidney Disease, published in Stem Cells Transl Med (2021) — summary generated from the PubMed abstract.
- 2021
Stem Cells Transl Med - Level BRandomized Controlled Trial
Clinical efficacy and safety of allogeneic adipose-derived stem cells ELIXCYTE in chronic kidney disease: a phase I/II study.
Randomized Controlled Trial on Chronic Kidney Disease, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cells Transl Med - Level BRandomized Controlled Trial
Periadventitial delivery of mesenchymal stem cells improves vascular remodeling and maturation in arteriovenous fistulas.
Randomized Controlled Trial on Chronic Kidney Disease, Chronic Inflammation, Autoimmune Research, published in Sci Transl Med (2025) — summary generated from the PubMed abstract.
- 2025
Sci Transl Med - Level BClinical Trial
Safety of Stromal Vascular Fraction Cell Therapy for Chronic Kidney Disease of Unknown Cause (Mesoamerican Nephropathy).
Clinical Trial with a reported sample of 18 on Chronic Kidney Disease, published in Stem Cells Transl Med (2023) — summary generated from the PubMed abstract.
- 2023
- n = 18
Stem Cells Transl Med - Level BClinical Trial
Allogeneic adipose tissue-derived stem cells ELIXCYTE ® in chronic kidney disease: A phase I study assessing safety and clinical feasibility.
Clinical Trial with a reported sample of 12 on Chronic Kidney Disease, published in J Cell Mol Med (2022) — summary generated from the PubMed abstract.
- 2022
- n = 12
J Cell Mol Med